Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Innovations in Oncology: Breast Cancer

Have you seen the new evidence supporting antibody-drug conjugates (ADCs) for the treatment of triple-negative breast cancer (TNBC)? Can you recognize treatment directions based on biomarkers, such as HER2-low and HER2 overexpression?

This educational series examines the rapidly evolving landscape of breast cancer treatment. Tune in to hear our globally renowned experts break down current and emerging ADCs that could benefit your patients with TNBC and HER2 breast cancer.

Provided by:

In Partnership with:

Episodes 1-2 of 2

Schedule16 Apr 2024